» Articles » PMID: 27451408

Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport

Overview
Specialty Pharmacology
Date 2016 Jul 25
PMID 27451408
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Accurate prediction of drug target activity and rational dosing regimen design require knowledge of drug concentrations at the target. It is important to understand the impact of processes such as membrane permeability, partitioning, and active transport on intracellular drug concentrations. The present study aimed to predict intracellular unbound atorvastatin concentrations and characterize the effect of enzyme-transporter interplay on these concentrations. Single-pass liver perfusion studies were conducted in rats using atorvastatin (ATV, 1 µM) alone at 4°C and at 37°C in presence of rifampin (RIF, 20 µM) and 1-aminobenzotriazole (ABT, 1 mM), separately and in combination. The unbound intracellular ATV concentration was predicted with a five-compartment explicit membrane model using the parameterized diffusional influx clearance, active basolateral uptake clearance, and metabolic clearance. Chemical inhibition of uptake and metabolism at 37°C proved to be better controls relative to studies at 4°C. The predicted unbound intracellular concentration at the end of the 50-minute perfusion in the +ABT , +ABT+RIF, and the ATV-only groups was 6.5 µM, 0.58 µM, and 5.14 µM, respectively. The predicted total liver concentrations and amount recovered in bile were within 0.94-1.3 fold of the observed value in all groups. The fold difference in total liver concentration did not always extrapolate to the fold difference in predicted unbound concentration across groups. Together, these results support the use of compartmental modeling to predict intracellular concentrations in dynamic organ-based systems. These predictions can provide insight into the role of uptake transporters and metabolizing enzymes in determining drug tissue concentrations.

Citing Articles

Using partition analysis as a facile method to derive net clearances.

Korzekwa K, Yadav J, Nagar S Clin Transl Sci. 2022; 15(8):1867-1879.

PMID: 35579201 PMC: 9372430. DOI: 10.1111/cts.13310.


Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Kulkarni P, Youssef A, Argikar A Methods Mol Biol. 2021; 2342:369-417.

PMID: 34272702 DOI: 10.1007/978-1-0716-1554-6_14.


Methods to Predict Volume of Distribution.

Holt K, Nagar S, Korzekwa K Curr Pharmacol Rep. 2021; 5(5):391-399.

PMID: 34168949 PMC: 8221585. DOI: 10.1007/s40495-019-00186-5.


Recent developments in and models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Yadav J, El Hassani M, Sodhi J, Lauschke V, Hartman J, Russell L Drug Metab Rev. 2021; 53(2):207-233.

PMID: 33989099 PMC: 8381685. DOI: 10.1080/03602532.2021.1922435.


A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.

Kulkarni P, Korzekwa K, Nagar S Xenobiotica. 2019; 50(5):536-544.

PMID: 31530243 PMC: 7065931. DOI: 10.1080/00498254.2019.1668982.


References
1.
Bossuyt X, Muller M, Meier P . Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol. 1996; 25(5):733-8. DOI: 10.1016/s0168-8278(96)80246-7. View

2.
Reinoso R, Telfer B, Brennan B, Rowland M . Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metab Dispos. 2001; 29(4 Pt 1):453-9. View

3.
Xiang X, Jada S, Li H, Fan L, Tham L, Wong C . Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics. 2006; 16(9):683-91. DOI: 10.1097/01.fpc.0000230420.05221.71. View

4.
Zhang W, He Y, Han C, Liu Z, Li Q, Fan L . Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol. 2006; 62(5):567-72. PMC: 1885174. DOI: 10.1111/j.1365-2125.2006.02686.x. View

5.
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang W . A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999; 274(52):37161-8. DOI: 10.1074/jbc.274.52.37161. View